CN106458998A - 吡嗪衍生物 - Google Patents

吡嗪衍生物 Download PDF

Info

Publication number
CN106458998A
CN106458998A CN201580024718.7A CN201580024718A CN106458998A CN 106458998 A CN106458998 A CN 106458998A CN 201580024718 A CN201580024718 A CN 201580024718A CN 106458998 A CN106458998 A CN 106458998A
Authority
CN
China
Prior art keywords
methyl
group
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580024718.7A
Other languages
English (en)
Chinese (zh)
Inventor
丸山明伸
竹内进
高桥良昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CN106458998A publication Critical patent/CN106458998A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
CN201580024718.7A 2014-05-13 2015-05-12 吡嗪衍生物 Pending CN106458998A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014099677 2014-05-13
JP2014-099677 2014-05-13
PCT/JP2015/063654 WO2015174417A1 (ja) 2014-05-13 2015-05-12 ピラジン誘導体

Publications (1)

Publication Number Publication Date
CN106458998A true CN106458998A (zh) 2017-02-22

Family

ID=54479954

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580024718.7A Pending CN106458998A (zh) 2014-05-13 2015-05-12 吡嗪衍生物

Country Status (28)

Country Link
US (1) US9856237B2 (enExample)
EP (1) EP3144306B1 (enExample)
JP (1) JP6173576B2 (enExample)
KR (1) KR20170004998A (enExample)
CN (1) CN106458998A (enExample)
AR (1) AR100403A1 (enExample)
AU (1) AU2015260300A1 (enExample)
CA (1) CA2948797A1 (enExample)
CY (1) CY1119876T1 (enExample)
DK (1) DK3144306T3 (enExample)
ES (1) ES2654434T3 (enExample)
HR (1) HRP20180122T1 (enExample)
HU (1) HUE035728T2 (enExample)
IL (1) IL248900A0 (enExample)
LT (1) LT3144306T (enExample)
ME (1) ME02978B (enExample)
MX (1) MX2016014693A (enExample)
NO (1) NO3144306T3 (enExample)
PH (1) PH12016502223A1 (enExample)
PL (1) PL3144306T3 (enExample)
PT (1) PT3144306T (enExample)
RS (1) RS56837B1 (enExample)
RU (1) RU2016148735A (enExample)
SG (1) SG11201609359WA (enExample)
SI (1) SI3144306T1 (enExample)
SM (1) SMT201800155T1 (enExample)
TW (1) TW201609702A (enExample)
WO (1) WO2015174417A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN116496198A (zh) * 2023-06-26 2023-07-28 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种4-羟基-2'-(1-苄基-5-硝基吡咯甲叉)-苯甲酰肼衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034922A1 (en) * 1997-02-05 1998-08-13 Sankyo Company, Limited Prophylactic or therapeutic agent for diabetic complication
CN101679244A (zh) * 2007-04-11 2010-03-24 橘生药品工业株式会社 5元杂环衍生物及其医药用途
CN103068801A (zh) * 2010-06-16 2013-04-24 亚德生化公司 硫代乙酸盐化合物、组合物及其使用方法
WO2014077285A1 (ja) * 2012-11-14 2014-05-22 帝人ファーマ株式会社 ピリジン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4397875B2 (ja) * 1997-02-05 2010-01-13 第一三共株式会社 糖尿病合併症予防薬又は治療薬
CN101012193A (zh) * 2003-01-02 2007-08-08 霍夫曼-拉罗奇有限公司 新cb 1受体反激动剂
JP2007145786A (ja) * 2005-11-30 2007-06-14 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034922A1 (en) * 1997-02-05 1998-08-13 Sankyo Company, Limited Prophylactic or therapeutic agent for diabetic complication
CN101679244A (zh) * 2007-04-11 2010-03-24 橘生药品工业株式会社 5元杂环衍生物及其医药用途
CN103068801A (zh) * 2010-06-16 2013-04-24 亚德生化公司 硫代乙酸盐化合物、组合物及其使用方法
WO2014077285A1 (ja) * 2012-11-14 2014-05-22 帝人ファーマ株式会社 ピリジン誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN116496198A (zh) * 2023-06-26 2023-07-28 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种4-羟基-2'-(1-苄基-5-硝基吡咯甲叉)-苯甲酰肼衍生物及其制备方法和应用

Also Published As

Publication number Publication date
KR20170004998A (ko) 2017-01-11
IL248900A0 (en) 2017-01-31
EP3144306B1 (en) 2017-11-15
ME02978B (me) 2018-10-20
AR100403A1 (es) 2016-10-05
PL3144306T3 (pl) 2018-04-30
WO2015174417A1 (ja) 2015-11-19
AU2015260300A1 (en) 2016-12-22
SG11201609359WA (en) 2016-12-29
PT3144306T (pt) 2018-01-08
HUE035728T2 (en) 2018-05-28
JP6173576B2 (ja) 2017-08-02
JPWO2015174417A1 (ja) 2017-04-20
MX2016014693A (es) 2017-02-23
US9856237B2 (en) 2018-01-02
EP3144306A1 (en) 2017-03-22
EP3144306A4 (en) 2017-03-22
CA2948797A1 (en) 2015-11-19
LT3144306T (lt) 2018-01-10
PH12016502223A1 (en) 2017-02-06
DK3144306T3 (en) 2018-01-02
TW201609702A (zh) 2016-03-16
RS56837B1 (sr) 2018-04-30
HRP20180122T1 (hr) 2018-02-23
SI3144306T1 (en) 2018-02-28
ES2654434T3 (es) 2018-02-13
CY1119876T1 (el) 2018-06-27
RU2016148735A (ru) 2018-06-19
RU2016148735A3 (enExample) 2018-06-19
SMT201800155T1 (it) 2018-05-02
US20170152242A1 (en) 2017-06-01
NO3144306T3 (enExample) 2018-04-14

Similar Documents

Publication Publication Date Title
JP6293068B2 (ja) ピリジン誘導体
BRPI0715326A2 (pt) compostos derivados de imidazolonas polissubstituÍdas, composiÇço farmacÊutica e, uso de pelo menos um composto
EP3162801B1 (en) Salt of halogen-substituted heterocyclic compound
CN104109115B (zh) 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
EA013408B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
WO2010007944A1 (ja) 含窒素二環性複素環化合物
TW200916098A (en) Agent for lowering uric acid level
CN106458998A (zh) 吡嗪衍生物
JP2015214527A (ja) イミダゾール誘導体
CN101544631B (zh) 吡唑类5-脂氧酶小分子抑制剂及其制备方法、药物组合物和应用
JP6021148B2 (ja) Ｌｓｔ−１及び／又はｌｓｔ−２によって輸送される化合物
JP5694959B2 (ja) 三位で置換された３−ベンゾフラニル−インドール−２−オン誘導体、この調製およびこの治療的使用
HK1230192A1 (en) Pyrazine derivative
CN114286677B (zh) 作为β-连环蛋白/TCF4相互作用调节剂的杂环化合物
CN106458970B (zh) 吡啶衍生物的多晶形体及其制造方法
HK1246280A1 (en) Pyridine derivative
JP2015214523A (ja) ピラジン置換イミダゾール誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230192

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1230192

Country of ref document: HK